Not quite - until now there have been no large scale studies on whether patients would really benefit from spheres as a first line treatment. A few smaller case studies have shown that patients benefited - to the point of tumour shrinkage for surgical resection. So the current results clarified that those cases are rare and not the norm.
450 patients are considered large.. this is not a "placebo trial". Its the normal treatment vs normal+spheres treatment. And it showed no statistically significant difference.
Thus far, i've not read any market release that says Sirtex sold spheres as a first line treatment. All revenue has been from salvage therapy.
Clinical Trial Objectives, page-17
-
- There are more pages in this discussion • 25 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add SRX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
17.8¢ |
Change
0.003(1.43%) |
Mkt cap ! $75.34M | |||
| Open | High | Low | Value | Volume |
| 17.8¢ | 17.8¢ | 17.5¢ | $9.047K | 50.98K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 15 | 7293686 | 17.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 18.0¢ | 1399496 | 11 |
View Market Depth
| Last trade - 15.01pm 26/07/2024 (20 minute delay) ? |
| SRX (ASX) Chart |